OMEICOS Therapeutics GmbH Email Format

Biotechnology ResearchBerlin, Germany2-10 Employees

OMEICOS Therapeutics GmbH is a Berlin-based biotechnology company focused on discovering and developing small molecule therapeutics derived from omega-3 fatty acid–derived epoxyeicosanoids, with potential to treat mitochondrial dysfunction, inflammatory and cardiovascular diseases. The company has identified synthetic, metabolically robust analogues that are orally available and exhibit improved biological activity and pharmacokinetic properties compared with the natural compounds. Its lead development program, OMT-28, is being evaluated in a PMD-OPTION Phase 2a clinical study in patients with Primary Mitochondrial Disease. OMEICOS operates with a small team of 2-10 employees and is located at 10 Robert-roessle-strasse, Berlin, Berlin 13125 Germany. Public reports indicate it has pursued external financing, including grant funding in 2023 and prior financing rounds in 2018-2019.

Sign up for free to view info

Company overview Employee directory